Related Experiment Videos

Pathogenetic and diagnostic aspects of dialysis-related amyloidosis

J Schaeffer1, J Floege, G Ehlerding

  • 1Division of Nephrology, Hannover Medical School, Germany.

Insights

Dialysis-related amyloidosis (DRA) is a significant complication in end-stage renal disease patients due to beta 2-microglobulin (beta 2-m) buildup. Kidney transplantation effectively halts the progression of this amyloidosis.

Area of Science:

  • Nephrology
  • Pathology
  • Medical Imaging

Background:

  • Dialysis-related amyloidosis (DRA) is a major cause of morbidity in patients with end-stage renal disease.
  • The retention of beta 2-microglobulin (beta 2-m) is the fundamental basis for DRA.
  • Pathogenesis involves alterations in beta 2-m metabolism, inflammation, and predisposing factors like age at dialysis onset.

Purpose of the Study:

  • To review the pathogenesis, clinical presentation, and diagnostic modalities of dialysis-related amyloidosis.
  • To highlight the role of beta 2-microglobulin in DRA development.
  • To discuss the impact of kidney transplantation on DRA progression.

Main Methods:

  • Review of existing literature on dialysis-related amyloidosis.
  • Analysis of pathogenetic concepts, clinical signs, and diagnostic tools.
  • Evaluation of the effect of successful kidney transplantation.

Main Results:

  • DRA is primarily caused by the accumulation of beta 2-microglobulin.
  • Clinical and radiological findings, along with sonographic synovial thickening, suggest DRA.
  • Histomorphological confirmation of beta 2m-amyloid is definitive; scintigraphy is a sensitive non-invasive tool.

Conclusions:

  • Successful kidney transplantation is crucial as it halts the progression of dialysis-related amyloidosis.
  • Understanding the multifactorial pathogenesis of DRA is key for patient management.
  • Advanced diagnostic tools aid in the definitive diagnosis and monitoring of DRA.

Related Concept Videos